Published in Liver Cancer on September 01, 2012
Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. Cancer Cell (2016) 1.46
The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int (2014) 1.03
Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways. Oncotarget (2015) 0.94
The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One (2014) 0.92
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio (2015) 0.92
New Insights into the Pathogenesis of Alcohol-Induced ER Stress and Liver Diseases. Int J Hepatol (2014) 0.90
Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget (2015) 0.89
Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget (2014) 0.88
Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity. Sci Rep (2015) 0.85
Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett (2014) 0.84
Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer (2013) 0.84
SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma. Int J Biol Sci (2014) 0.84
Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer (2015) 0.84
The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling. J Cancer (2015) 0.83
Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells. Biomed Res Int (2014) 0.81
Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol (2015) 0.80
Prognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma. Cell Death Dis (2015) 0.78
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget (2016) 0.78
MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway. Oncotarget (2017) 0.77
Restitution of gene expression and histone acetylation signatures altered by hepatitis B virus through antiviral microRNA-like molecules in nontransformed murine hepatocytes. Clin Epigenetics (2014) 0.76
Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages. PLoS One (2016) 0.76
Emerging roles of FGF signaling in hepatocellular carcinoma. Transl Cancer Res (2016) 0.76
The noncoding RNA HOXD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinoma. Mol Cancer (2017) 0.76
Molecular Pathogenesis of Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
CAPS1 Negatively Regulates Hepatocellular Carcinoma Development through Alteration of Exocytosis-Associated Tumor Microenvironment. Int J Mol Sci (2016) 0.75
Association between FOXM1 and hedgehog signaling pathway in human cervical carcinoma by tissue microarray analysis. Oncol Lett (2016) 0.75
Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget (2016) 0.75
New Insights into the Epigenetics of Hepatocellular Carcinoma. Biomed Res Int (2017) 0.75
Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma. Int J Mol Med (2016) 0.75
Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention. World J Hepatol (2016) 0.75
VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol (2016) 0.75
The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling. Biomed Res Int (2015) 0.75
Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. Oncotarget (2017) 0.75
Downregulation of VANGL1 inhibits cellular invasion rather than cell motility in hepatocellular carcinoma cells without stimulation. Genet Test Mol Biomarkers (2015) 0.75
Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget (2016) 0.75
Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model. Oncotarget (2016) 0.75
Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of Galectin-3 in Hepatocellular carcinoma. Sci Rep (2017) 0.75
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases (2015) 0.75
β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study. Virchows Arch (2015) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 6.87
Notch1 functions as a tumor suppressor in mouse skin. Nat Genet (2003) 6.76
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics (1999) 6.23
The double-edged sword of autophagy modulation in cancer. Clin Cancer Res (2009) 5.46
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer (2003) 4.75
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A (2009) 3.10
Notch signaling controls liver development by regulating biliary differentiation. Development (2009) 2.93
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nat Rev Genet (2008) 2.80
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Epigenetics in cancer: what's the future? Oncology (Williston Park) (2011) 2.70
Clinical studies of histone deacetylase inhibitors. Clin Cancer Res (2009) 2.68
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res (2003) 1.92
Hedgehog signaling in the liver. J Hepatol (2010) 1.80
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology (2004) 1.73
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer (2005) 1.73
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62
Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology (1997) 1.50
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy (2010) 1.47
The Hippo pathway in biological control and cancer development. J Cell Physiol (2011) 1.44
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer (2011) 1.43
Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One (2011) 1.37
Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol (1997) 1.36
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer (2007) 1.33
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology (2007) 1.21
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol (2009) 1.14
Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther (2006) 1.13
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology (2006) 1.12
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One (2010) 1.05
The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol (2010) 1.04
Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep (2012) 0.85
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol (2009) 1.52
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21
Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol (2009) 1.17
Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07
Gene signatures in the management of hepatocellular carcinoma. Semin Oncol (2012) 1.02
Signaling pathways in hepatocellular carcinoma. Oncology (2011) 0.98
Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology (2012) 0.88
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 0.88
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (2012) 0.85
Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol (2008) 0.85
miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology (2010) 0.84
Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol (2013) 0.84
Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res (2011) 0.84
Why men are at higher risk for hepatocellular carcinoma? J Hepatol (2012) 0.82
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl (2006) 0.82
[Cell biology and genetics in liver cancer]. Gastroenterol Hepatol (2007) 0.80
microRNAs: new ways to block tumor angiogenesis? J Hepatol (2012) 0.79
Transplantation for hepatocellular carcinoma--worth waiting for? Liver Transpl (2014) 0.75
Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. Eur J Gastroenterol Hepatol (2006) 0.75
Genomic tracing of the elusive liver cancer ancestor. J Hepatol (2010) 0.75
Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. J Hepatol (2011) 0.75
Genetically engineered mouse models: future tools to predict clinical trial results in oncology? Future Oncol (2013) 0.75
[Genomic prognostic markers in hepatocellular carcinoma]. Gastroenterol Hepatol (2011) 0.75